Behavioral interventions during and after treatment significantly reduce rebound risk
This precision-informed approach maximizes both affordability and clinical fit
Retatrutide is currently under clinical investigation, with the most significant data emerging from Phase 2 trials conducted primarily in the United States
GLP-1RA-mediated benefits on blood pressure accounted for 15% weight loss could induce reversal of early-stage chronic kidney disease and microalbuminuria at 24 months follow-up [73]
In the regulation of innate immunity, the lack of the expression of NRF-2 entails a disturbance in the protective process of the host, as well as increased damage by hyperoxia, the increase of ROS, and inefficiency in the elimination and increase in the production of proinflammatory cytokines [28,29]
Patients and clinicians increasingly turn to dietary strategies such as KD, originally developed to treat epilepsy, for weight loss